Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLN0264 in Asian Patients with Advanced GI Carcinoma
NCT02391038Phase 1Terminated
- Sponsor
- Millennium Pharmaceuticals
- Start
- Dec 2014
- Primary completion
- Oct 2015
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of indusatumab vedotin in gastrointestinal carcinoma, gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Millennium Pharmaceuticals. Primary endpoints: Number of Participants Reporting One or More Treatment-emergent Adverse Events, Number of Participants Reporting One or More Serious Adverse Events and 12 more. Started Dec 2014; status: terminated.
02
Drugs
indusatumab vedotin
03
Conditions
gastrointestinal carcinomagastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02391038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02391038.